|Table of Contents|

Research status of molecular therapy for advanced pancreatic cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 06
Page:
1108-1112
Research Field:
Publishing date:

Info

Title:
Research status of molecular therapy for advanced pancreatic cancer
Author(s):
WANG Dan; FAN Xiaona; LI Qingwei; LI Zhiwei
Department of Gastrointestinal Medical Oncology,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150001,China.
Keywords:
pancreatic cancer; targeted therapy; immunotherapy; tumor vaccine; tumor stem cells; tumor stroma; tumor mesenchyme
PACS:
R735.9
DOI:
10.3969/j.issn.1672-4992.2022.06.033
Abstract:
Pancreatic cancer （PDAC）is the seventh most deadly malignancy worldwide.It is the second and third leading cause of gastrointestinal malignancies and cancer-related deaths,respectively,in the US.Compared to other malignancies,advanced PDAC has the lowest survival rate,with a median overall survival of 2~8 months and a 5-year survival of 8.5%.The treatment of pancreatic cancer is very difficult,which brings great challenges to clinicians.At present,the treatment of advanced pancreatic cancer is scarce,and chemotherapy is still the main treatment method.Although chemotherapy can temporarily control the progress of the disease,it is unsatisfactory in terms of prolonged survival.Molecular targeted therapy has achieved milestone achievements in other tumor types,such as lung cancer,colorectal cancer,etc,but molecular targeted therapy in patients with advanced pancreatic cancer has not achieved significant results.This requires us to find new therapeutic targets and drugs.Based on the signal transduction pathway and tumor microenvironment of pancreatic cancer,this article summarizes and analyzes the research status of molecular therapy for advanced pancreatic cancer,and explores the development direction of future pancreatic cancer treatment.

References:

［1］ARE C,CHOWDHURY S,AHMAD H,et al.Predictive global trends in the incidence and mortality of pancreatic cancer based on geographic location,socio-economic status,and demographic shift［J］.Journal of Surgical Oncology,2016,114(6):736-742.
［2］SIEGEL RL,MILLER KD,JEMAL A,et al.Cancer statistics,2020［J］.CA:A Cancer Journal for Clinicians,2020,70(1):7-30.
［3］SANTOSREBELO A,KUMAR P,PILLAY V,et al.Development and mechanistic insight into the enhanced cytotoxic potential of parvifloron D albumin nanoparticles in EGFR-overexpressing pancreatic cancer cells［J］.Cancers,2019,11(11):1733.
［4］HUANG J,LIU J,QIU L,et al.Transient receptor potential vanilloid 1 promotes EGFR ubiquitination and modulates EGFR/MAPK signalling in pancreatic cancer cells［J］.Cell Biochemistry and Function,2020，10(10):1002.
［5］JIANG H,LIU X,KNOLHOFF BL,et al.Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion［J］.Gut,2020,69(1):122-132.
［6］VICKERS MM,POWELL E,ASMIS T,et al.Comorbidity,age and overall survival in patients with advanced pancreatic cancer -Results from NCIC CTG PA.3:A phase III trial of gemcitabine plus erlotinib or placebo［J］.European Journal of Cancer,2012,48(10):1434-1442.
［7］SCHULTHEIS B,REUTER D,EBERT MP,et al.Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer:a multicenter,randomized phase IIb study［J］.Annals of Oncology,2017,28(10):2429-2435.
［8］MUTGAN AC,BESIKCIOGLU HE,WANG S,et al.Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer［J］.Molecular Cancer,2018,17(1):66.
［9］KO AH,CUBILLO A,KUNDRANDA M,et al.LBA29CARRIE:A randomized,double-blind,placebo-controlled phase II study of istiratumab(MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer［J］.Annals of Oncology,2018,29(10):1093.
［10］INNOCENTI F,JIANG C,SIBLEY AB,et al.Genetic variation determines VEGF-A plasma levels in cancer patients［J］.Scientific Reports,2018,8(1):16332.
［11］YAN X,HUI Y,HUA Y,et al.EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway.［J］.Biomedicine & Pharmacotherapy,2019,109(10):762-769.
［12］KINDLER HL,NIEDZWIECKI D,HOLLIS D,et al.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer:phase III trial of the cancer and leukemia group B(CALGB 80303)［J］.Journal of Clinical Oncology,2010,28(22):3617-3622.
［13］RENI M,CEREDA S,MILELLA M,et al.Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma:A phase II randomised trial［J］.European Journal of Cancer,2013,49(17):3609-3615.
［14］ONEIL BH,SCOTT AJ,MA WW,et al.A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer［J］.Ann Oncol,2016,27(6):1180.
［15］CHUNG V,MCDONOUGH S,PHILIP PA,et al.Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy:SWOG S1115 study randomized clinical trial［J］.JAMA Oncology,2017,3(4):516-522.
［16］ESO Y,SHIMIZU T,TAKEDA H,et al.Microsatellite instability and immune checkpoint inhibitors:toward precision medicine against gastrointestinal and hepatobiliary cancers［J］.Journal of Gastroenterology,2020,55(1):15-26.
［17］QIAO XW,JIANG J,PANG X,et al.The evolving landscape of PD-1/PD-L1 pathway in head and neck cancer［J］.Front Immunol,2020,11:1721.
［18］WEISS GJ,WAYPA J,BLAYDORN L,et al.A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer(PembroPlus)［J］.British Journal of Cancer,2017,117(1):33-40.
［19］MARK H O' HARA.A phase II,open-label,randomized controlled clinical study of gemcitabine/albumin-bound paclitaxel±nivolumab±CD40 agonist monoclonal antibody in newly treated and metastatic pancreatic ductal adenocarcinoma patients［R］.America:ASCO-GI,2021.
［20］ROYAL RE,LEVY C,TURNER K,et al.Phase 2 trial of single agent ipilimumab(Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma［J］.Journal of Immunotherapy,2010,33(8):828-833.
［21］AGLIETTA M,BARONE C,SAWYER M,et al.A phase I dose escalation trial of tremelimumab(CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer［J］.Annals of Oncology,2014,25(9):1750-1755.
［22］SUN D,MA J,WANG J,et al.Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer:a real-world study in Chinese cohort［J］.Therapeutics and Clinical Risk Management,2018，14(1):1691-1700.
［23］COVELER AL,ROSSI GR,VAHANIAN NN,et al.Algenpantucel-L immunotherapy in pancreatic adenocarcinoma［J］.Immunotherapy,2016,8(2):117-125.
［24］WU AA,BEVER KM,HO WJ,et al.A phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine(GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer［J］.Clin Cancer Res,2020,26(19):5129-5139.
［25］TSUJIKAWA T,CROCENZI T,DURHAM JN,et al.Evaluation of cyclophosphamide/GVAX pancreas followed by listeria-mesothelin(CRS-207) with or without nivolumab in patients with pancreatic cancer［J］.Clin Cancer Res,2020,26(14):3578-3588.
［26］XU H,ZHOU Y,LI W,et al.Tumor derived mesenchymal stem cell secreted IL 6 enhances resistance to cisplatin via the STAT3 pathway in breast cancer［J］.Oncology Letters,2018,15(6):9142-9150.
［27］DE JESUSACOSTA A,SUGAR EA,ODWYER PJ,et al.Phase 2 study of vismodegib,a hedgehog inhibitor,combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma［J］.British Journal of Cancer,2020,122(4):498-505.
［28］SONBOL MB,AHN DH,GOLDSTEIN D,et al.CanStem111P trial:A phase III study of napabucasin plus nab-paclitaxel with gemcitabine［J］.Future Oncology,2019,15(12):1295-1302.
［29］PARK D,SHAKYA R,KOIVISTO C,et al.Murine models for familial pancreatic cancer:Histopathology,latency and drug sensitivity among cancers of Palb2,Brca1 and Brca2 mutant mouse strains［J］.PLoS One,2019,14(12):1-2.
［30］TALIA GOLAN,PASCAL HAMMEL,MICHELE RENI,et al.Overallsurvival from the phase 3 POLO trial:Maintenance olaparib for germlineBRCA-mutated metastatic pancreatic cancer［R］.America:ASCO-GI,2021.
［31］BORAD MJ,REDDY SG,BAHARY N,et al.Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer［J］.Journal of Clinical Oncology,2015,33(13):1475-1481.
［32］UNDERWOOD PW,ZHANG DY,CAMERON ME,et al.Nicotine induces IL-8 secretion from pancreatic cancer stroma and worsens cancer-induced cachexia［J］.Cancers(Basel),2020,12(2):10-11.
［33］YANG X,LIU S,XU J,et al.Pancreatic stellate cells increase pancreatic cancer cells invasion through the hepatocyte growth factor/c-Met/survivin regulated by P53/P21［J］.Experimental Cell Research,2017,357(1):79-87.
［34］HINGORANI SR,HARRIS WP,BECK JT,et al.Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer［J］.Clinical Cancer Research,2016,22(12):2848-2854.
［35］HINGORANI SR,ZHENG L,BULLOCK AJ,et al.HALO 202:randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated,metastatic pancreatic ductal adenocarcinoma［J］.Journal of Clinical Oncology,2017,36(4):359-366.
［36］RAMANATHAN RK,MCDONOUGH S,PHILIP PA,et al.Phase Ib/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma:SWOG S1313［J］.Journal of Clinical Oncology,2019,37(13):1062-1069.
［37］JIN MH,NAM A,PARK JE,et al.Therapeutic co-targeting of WEE1 and ATM downregulates PD-L1 expression in pancreatic cancer［J］.Cancer Research and Treatment,2020,52(1):149-166.
［38］CUNEO KC,MORGAN MA,SAHAI V,et al.Dose escalation trial of the Wee1 inhibitor adavosertib(AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer［J］.Journal of Clinical Oncology,2019,37(29):2643-2650.

Memo

Memo:
-
Last Update: 1900-01-01